retatrutide triple agonist glp-1 gip glucagon #retatrutide is a novel peptide at the receptor, receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter https://t.co/duYwW0EcmF The TRIUMPH-1 Phase 3 results

The providers documented cause not the ferritin level alone determines which code to assign

As both hormones fluctuate and eventually decrease, the metabolic environment that once supported weight maintenance changes

Factory calibration removes routine fingersticks: Earlier Medtronic sensors required fingerstick calibrations every 12 hours to maintain accuracy

For many patients, that makes long-term planning just as important as the weight loss itself

Unlike its effect on Complex I activity, NAC could not recover cytochrome c oxidase activity in GSH-depleted cells treated with 10 mol/ml ASA suggesting higher sensitivity of the enzyme towards ASA/GSH-depletion